Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 07, 2022 07:00 ET | Source: Immatics N.V.

Immatics und Editas Medicine schließen strategische Forschungskollaboration zur Kombination von gamma-delta T-Zelltherapien mit Gene-Editing-Technologien für die Behandlung von Krebs ab

Tübingen, Deutschland, Houston, Texas und Cambridge, Massachusetts, 7. Juni 2022 – Immatics N.V. (Nasdaq: IMTX, „Immatics“), ein Unternehmen, das sich auf die Entwicklung und Herstellung von...
April 12, 2021 20:30 ET | Source: DelveInsight Business Research LLP

CRISPR Therapies Pipeline Insights 2021: Analysis of Key Companies, Emerging Therapies, Recent Happenings and Futuristic Trends

Los Angeles, USA, April 12, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapies Pipeline Insights 2021: Analysis of Key Companies, Emerging Therapies, Recent Happenings and Futuristic Trends The leading...
August 06, 2019 16:01 ET | Source: Editas Medicine, Inc.

Editas Medicine Appoints Cynthia Collins as President and Chief Executive Officer

CAMBRIDGE, Mass., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that its Board of Directors has unanimously appointed...
April 03, 2019 07:00 ET | Source: Editas Medicine, Inc.

Editas Medicine and BlueRock Therapeutics Enter Strategic Research Collaboration and Cross-Licensing Agreement to Combine Genome Editing and Cell Therapy Platforms

– Collaboration enables BlueRock to discover and develop engineered cell medicines broadly across neurology, cardiology and immunology – – Collaboration enables Editas Medicine to discover and...
February 28, 2019 09:00 ET | Source: Editas Medicine, Inc.

Editas Medicine Supports Global Movement to Raise Awareness on Rare Disease Day®

CAMBRIDGE, Mass., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, announced today the Company is joining forces with the nearly 30 million...
February 06, 2019 09:00 ET | Source: Editas Medicine, Inc.

Editas Medicine Names David Scadden, M.D., to Board of Directors

CAMBRIDGE, Mass., Feb. 06, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that it has appointed David T. Scadden, M.D., to its Board...
January 22, 2019 09:00 ET | Source: Editas Medicine, Inc.

Editas Medicine Announces Chief Executive Officer Transition

Katrine Bosley to Step Down as President and CEO Director Cynthia Collins to Serve as Interim CEO Board of Directors Initiates Search for Permanent Successor CAMBRIDGE, Mass., Jan. 22, 2019 ...
January 21, 2019 11:00 ET | Source: Editas Medicine, Inc.

Editas Medicine Announces Publication in Nature Medicine of Data Supporting the Development of EDIT-101 to Treat Leber Congenital Amaurosis 10 (LCA10)

CAMBRIDGE, Mass., Jan. 21, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the journal Nature Medicine published the comprehensive,...
January 07, 2019 09:00 ET | Source: Editas Medicine, Inc.

Editas Medicine Reports on Recent Progress at J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 07, 2019 (GLOBE NEWSWIRE) -- In a presentation to investors on Wednesday, January 9, 2019, at 9:00 a.m. PST at the 37th Annual J.P. Morgan Healthcare Conference, Editas...
January 02, 2019 08:30 ET | Source: Editas Medicine, Inc.

Editas Medicine to Present at the 37th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present a company overview followed by a...

Next Page keyboard_arrow_right